Marijuana users found to have 16% lower fasting insulin levels than non-users
Marijuana use has been associated with lower fasting insulin levels
<p> </p> <div> People who smoke marijuana have been found to have 16 per cent lower fasting insulin levels than non-users, according to research published in The American Journal of Medicine.</div> <div> </div> <div> In light of the findings, professor of medicine at the University of Arizona College of Medicine, Tucson, Joseph Albert, called for more basic and clinical research into the short and long-term effects of marijuana in a variety of clinical settings, including cancer and diabetes. </div> <div> </div> <div> Data from 4,657 patients who completed a drug questionnaire was used to inform the research. Some 579 were current marijuana users, while 1,975 had used it in the past. </div> <div> </div> <div> Those who reported using marijuana in the past month had lower levels of fasting insulin and HOMA-IR. The link was weaker in candidates that reported using marijuana at least once, but not in the past 30 days. </div> <div> </div> <div> Professor Albert commented: "These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions."</div> <div> </div> <div> Previous studies have shown that while marijuana users tend to take in more calories, they often have lower body mass indexes and smaller waist circumferences. </div>
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.